Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Pfizer Inc. has initiated a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, a selective and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other gastrointestinal (GI) disorders. The Phase 1 clinical trial is designed to test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects. In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan's motilin agonist program, including KOS-2187 and related compounds, in a transaction potentially valued at $250 million for the successful development and commercialization of PF-04548043 for one indication as well as royalties on worldwide sales.

"Kosan today has four advancing clinical programs, underscoring the increasing value of our development pipeline," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Consistent with Kosan's focus on oncology, we successfully out-licensed KOS-2187 and our motilin receptor agonist program to Pfizer, a company with a strong gastrointestinal capability that could best exploit its therapeutic and commercial potential. We appreciate Pfizer's commitment to the development and potential commercialization of this promising prokinetic compound and look forward to its rapid advancement through the clinic."

About PF-04548043 and Motilin Receptor Agonists

Motilin, a hormone secreted by the small intestine, stimulates gastrointestinal motility (movement). The activity of motilin is mediated through the G-protein coupled
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2008)...velopment Initiative bring MJFF,s,current active i...y 20,2009, NEW YORK, July 22 /PRNewswire-USNewsw...f transformative treatments and a cure for Parkins...rkinson,s Research has awarded,$2.7 million in tot...rds,were granted under MJFF,s Therapeutics Develop...
(Date:7/22/2008)... Apidra(R) Resulted in Significant, Reductions in ... Algorithm Used, ...s from the "Adjust to,Target in Type 2 Diabetes: C...unting for Adjustment of Mealtime Insulin Glulisin...Association,s (ADA) medical journal,Diabetes Care...
(Date:7/22/2008)...a University Medical Center Based on Ros...The Test Differentiates Squamous From Non-Squamous...Squamous-Cell Carcinoma of the Lung With Se...ent,This is the First CLIA Approved Test Which Lev...rs for Accurate Diagnosis of Lung Cancer, REHOVOT...
(Date:7/22/2008)...ew Approach of LASH (Laser Assisted Scar Heali...y, MARSEILLES, France, July 22 /- Ek...omedicine company, which develops first-in-class,l...duction, announced today,the publication of a scie...reporting the results of a pilot study on cutaneou...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3CEL SCI Corporation Releases Letter to Shareholders 10228 1CEL SCI Corporation Releases Letter to Shareholders 10228 2CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 1CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 2CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 3CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 4Clontech Laboratories Inc Releases the ProteoTuner 28TM 29 Systems 2762 1Clontech Laboratories Inc Releases the ProteoTuner 28TM 29 Systems 2762 2Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic 2759 1Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic 2759 2
...GLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS...biopharmaceutical,company developing small molecul...metabolic diseases, today announced positive,resul...lerating,gastric emptying in diabetic patients wit...tudy were presented at the American,Diabetes Assoc...
...technology Company updates progress and upcoming,m...26, 2007 /PRNewswire-FirstCall/ - SemBioSys,Geneti...tfolio of,therapeutic proteins for metabolic and c...eclinical data supporting the,development of plant...esented its findings at the 67th Scientific Sessio...
Other Medicine Technology:Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 2Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
(Date:7/25/2008)... Though the number of jobs created in the me...es reported a different kind of slowdown: they lai.... , Seattle, WA (PRWEB) J...in the medical field slowed in June overall, pharm...lowdown that will be music to the ears of sales re...
(Date:7/25/2008)...rporation Executive, Robert J. Reilly, Joins Aetho...n Inc.,( http://www.aethon.com ), the leading deve... logistics, today announced that Robert J. Reilly ... Chief Financial Officer., Reilly, who was most r...sson Corporation,s Specialty Pharmacy Division, br...
(Date:7/25/2008)...ack-up in esophagus can cause immune system change...- The first evidence linking gastroesophageal refl...y Duke University Medical Center researchers. ,...st noted in the 1970s, and since then studies have...sthma patients also experience GERD symptoms. But ...
(Date:7/25/2008)... The Drug Information Association (DIA) and ...he Critical Path Initiative (CPI) on the Move: Com...da, MD) and the Critical Path Transporter Workshop... Horsham, PA (PRWEB) July 25, 2005-- T...ociation (DIA)] and the Food and Drug Administrati...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3
...Researchers have uncovered important information a...zed DNA, a critical step in DNA mutation that has ...at appears in the August edition of the Journal of... Georgia Institute of Technology have reported unc...
...The cells and receptors responsible for sour taste...titute researcher Charles S. Zuker and Nicholas J....er seven years of working together to identify the...r three of the five tastes humans can sense -- swe...
...Aromatherapy, the treatment using scents, is one o...ne. It is a holistic treatment of caring for the ...t is widely used at home, clinics and hospitals fo...in relief for women in labor pain, relieving pain ...
...The Beijing Health Bureau confirmed on Friday the .... About 3,142 HIV carriers and AIDS patients were...ing according to Statistics from the Beijing Healt...re discovered in the first six months of the year....
Other Medicine News:Health News:Elusive Step In DNA Mutation Uncovered By Researchers 2Health News:Elusive Step In DNA Mutation Uncovered By Researchers 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 4Health News:Sour Taste Sensors Identified 2Health News:Sour Taste Sensors Identified 3Health News:Benefits Of Aromatherapy 2Health News:Benefits Of Aromatherapy 3Health News:Benefits Of Aromatherapy 4
Portable Compressor Nebulizer
The 50 psi MaxiCompressor, the workhorse of compressors, is designed to run 24 hours a day, 7 days a week. It features a tamper-proof locking regulator valve to guard against unintentional increases
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel
The very popular and competitively priced SportNeb features a 35 PSI, die-cast aluminum compressor. Design enhancements include a neb kit holder, built-in cord storage and optional black carry bag. T
Medicine Products: